120.86 0.00 (0.00%)
After hours: 4:48PM EST
|Bid||113.00 x 1000|
|Ask||122.75 x 800|
|Day's Range||120.46 - 122.84|
|52 Week Range||98.56 - 278.62|
|Beta (3Y Monthly)||1.85|
|PE Ratio (TTM)||20.28|
|Earnings Date||Feb 19, 2019 - Feb 25, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||217.33|
Key highlights of the week were fourth-quarter results from Regeneron Pharmaceuticals and Ligand Pharmaceuticals along with other regulatory and pipeline updates.
Merrimack (MACK) regains its status as a development-stage biopharma company after the sale of its sole marketed product Onivyde in 2017.
Ligand Pharmaceuticals Inc NASDAQ NMS:LGNDView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is high * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is extremely high for LGND with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting LGND. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding LGND totaled $1.12 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Ligand (LGND) delivered earnings and revenue surprises of 33.86% and 10.01%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the San Diego-based company said it had a loss of $2.02. Earnings, adjusted for one-time gains and costs, came to $1.70 per share. The drugmaker posted revenue of $59.6 million in ...
Conference Call Begins at 4:30 p.m. Eastern Time TodayAnalyst day to be held on Tuesday March 12 at 10:00 a.m. Eastern Time in New York City
Ligand Pharmaceuticals Incorporated (LGND) announces it has entered into a worldwide OmniAb partnership with Genagon Therapeutics AB, an immuno-oncology focused biotech located in Sweden. Ligand received an upfront payment and is eligible to receive development milestone payments and tiered royalties for each product incorporating an OmniAb-derived antibody. “This agreement gives Genagon access to an industry-leading antibody discovery technology and the only platform to offer access to three species that produce fully-human antibodies.
Ligand Pharmaceuticals Incorporated (LGND) announces closing an investment in Dianomi Therapeutics, Inc., a biopharmaceutical company focused on improving the delivery and efficacy of large and small molecules in the treatment of a variety of diseases and on therapies for inflammatory diseases, such as osteoarthritis and pain. Ligand paid a total of $3 million to Dianomi in exchange for 1) a tiered royalty of two or three percent based on level of net sales for the first five products to be approved using Dianomi’s patented Mineral Coated Microparticle (MCM) technology and 2) a loan convertible into $1 million of equity at the next qualified financing. Ligand will provide technical and scientific advisory assistance to Dianomi for one year.
NEW YORK, Feb. 01, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Bragar Eagel & Squire, P.C. is investigating potential claims against Ligand Pharmaceuticals Incorporated (LGND). Our investigation concerns whether Ligand has violated the federal securities laws and/or engaged in other unlawful business practices. Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning our investigation into Ligand Corporation please go to https://bespc.com/lgnd/.
Proceeds from financing completed simultaneously with reverse merger to be used to fund pipeline which includes programs licensed from Ligand
Seelos Therapeutics, Inc. (Nasdaq:SEEL), a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders, announced today the completion of its previously disclosed merger with Apricus Biosciences, Inc. The combined company changed its name to Seelos Therapeutics, Inc. and will focus on the development and commercialization of CNS therapeutics with known mechanisms of action in areas with a highly unmet medical need. Seelos is expected to begin trading today, January 24, 2019, on The Nasdaq Capital Market under the ticker symbol “SEEL”. The previous ticker symbol was “APRI” (APRI). Seelos will maintain its headquarters in New York, New York and will be led by Chairman and Chief Executive Officer, Raj Mehra, Ph.D.
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders Read More...
The law firm of Kirby McInerney LLP is investigating potential claims against Ligand Pharmaceuticals Incorporated (“Ligand” or the “Company”) (NASDAQ: LGND). This investigation concerns whether Ligand has violated federal securities laws and/or engaged in other unlawful business practices. On January 16, 2019, Citron Research published a report entitled “Pipeline Ligand Pipe Dream,” detailing sources of Ligand’s future revenues by drug candidate, showing how roughly 60% of the Company’s milestone payments stem from just two companies.
Viking Therapeutics fell earlier this week after Citron Research released a bearish report on licensor Ligand Pharma, but shares recovered on Thursday.
NEW YORK, Jan. 17, 2019 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Ligand Pharmaceuticals.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Jan. 16) Avenue Therapeutics Inc (NASDAQ: ATXI ) BioDelivery ...